Article info
PDFBasic Science
Dasatinib (BMS-35482) Interacts Synergistically With Docetaxel, Gemcitabine, Topotecan, and Doxorubicin in Ovarian Cancer Cells With High SRC Pathway Activation and Protein Expression
- Address correspondence and reprint requests to Angeles Alvarez Secord, MD, MHSc, DUMC 3079, Division of Gynecologic Oncology, Duke University Medical Center, Erwin Road, 27710, Durham, NC 27710. E-mail: secor002{at}mc.duke.edu.
Citation
Dasatinib (BMS-35482) Interacts Synergistically With Docetaxel, Gemcitabine, Topotecan, and Doxorubicin in Ovarian Cancer Cells With High SRC Pathway Activation and Protein Expression
Publication history
- Received October 7, 2013
- Accepted November 11, 2013
- First published February 1, 2014.
Online issue publication
June 18, 2019
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© 2014 by the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology.